Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

This study tests a new drug called MDX2003 in patients with various types of B-cell lymphomas (blood cancers affecting white blood cells) that have come back or stopped responding to at least two prior treatments. It is a dose-finding and dose-expansion trial to evaluate safety and effectiveness. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a B-cell lymphoma (including large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, or related types) - Your cancer has relapsed or progressed after at least 2 prior treatments - Your tumor cells test positive for CD19 or CD20 - You have at least one measurable lesion on imaging - Your general health (ECOG 0–2) and organ function meet study requirements **You may NOT be eligible if...** - You have a history of hemophagocytic lymphohistiocytosis (HLH), a rare severe immune reaction - You have cancer involving the brain (CNS lymphoma) - You are on chronic steroids or immunosuppressants - You have HIV, active hepatitis B or C - You have had a prior organ or tissue transplant (except corneal) - You have a seizure disorder currently requiring medication - You have unresolved side effects from prior treatments Talk to your doctor to see if this trial is right for you.